These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 14649216)

  • 1. Fidarestat. Sanwa Kagaku/NC Curex/Sankyo.
    Giannoukakis N
    Curr Opin Investig Drugs; 2003 Oct; 4(10):1233-9. PubMed ID: 14649216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Aldose reductase inhibitor SNK-860].
    Hibi C
    Nihon Rinsho; 1997 Nov; 55 Suppl():212-5. PubMed ID: 9434469
    [No Abstract]   [Full Text] [Related]  

  • 3. Drug evaluation: ranirestat--an aldose reductase inhibitor for the potential treatment of diabetic complications.
    Giannoukakis N
    Curr Opin Investig Drugs; 2006 Oct; 7(10):916-23. PubMed ID: 17086937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Fidarestat (SNK-860)].
    Hibi C
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():594-600. PubMed ID: 12387056
    [No Abstract]   [Full Text] [Related]  

  • 5. Aldose reductase inhibition for diabetic neuropathy.
    Lancet; 1983 Oct; 2(8356):969. PubMed ID: 6138528
    [No Abstract]   [Full Text] [Related]  

  • 6. Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review.
    Schemmel KE; Padiyara RS; D'Souza JJ
    J Diabetes Complications; 2010; 24(5):354-60. PubMed ID: 19748287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Diabetic neuropathy: treatment trial with an aldose reductase inhibitor (Sorbinil)].
    Christensen JE; Larsen AB; Gregersen G
    Ugeskr Laeger; 1987 Nov; 149(46):3111-4. PubMed ID: 3127975
    [No Abstract]   [Full Text] [Related]  

  • 8. Ruboxistaurin (Eli Lilly).
    Wheeler GD
    IDrugs; 2003 Feb; 6(2):159-63. PubMed ID: 12789620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study.
    Hotta N; Toyota T; Matsuoka K; Shigeta Y; Kikkawa R; Kaneko T; Takahashi A; Sugimura K; Koike Y; Ishii J; Sakamoto N;
    Diabetes Care; 2001 Oct; 24(10):1776-82. PubMed ID: 11574441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of myo-inositol and sorbinil studies.
    Clements RS
    Clin Physiol; 1985; 5 Suppl 5():90-3. PubMed ID: 3938689
    [No Abstract]   [Full Text] [Related]  

  • 11. Structure of aldehyde reductase holoenzyme in complex with the potent aldose reductase inhibitor fidarestat: implications for inhibitor binding and selectivity.
    El-Kabbani O; Carbone V; Darmanin C; Oka M; Mitschler A; Podjarny A; Schulze-Briese C; Chung RP
    J Med Chem; 2005 Aug; 48(17):5536-42. PubMed ID: 16107153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can aldose reductase inhibition ameliorate diabetic neuropathy?
    González ER
    JAMA; 1981 Sep; 246(11):1169-70. PubMed ID: 6790734
    [No Abstract]   [Full Text] [Related]  

  • 13. Erythrocytic sorbitol contents in diabetic patients correlate with blood aldose reductase protein contents and plasma glucose levels, and are normalized by the potent aldose reductase inhibitor fidarestat (SNK-860).
    Asano T; Saito Y; Kawakami M; Yamada N; Sekino H; Hasegawa S;
    J Diabetes Complications; 2004; 18(6):336-42. PubMed ID: 15531183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ["Diabetic autonomic neuropathy" series. Epidemiology, pathogenesis, basic therapy and prognosis].
    Luft D
    MMW Fortschr Med; 2002 May; 144(20):47-50. PubMed ID: 12119885
    [No Abstract]   [Full Text] [Related]  

  • 15. Aldose reductase inhibitors: the end of an era or the need for different trial designs?
    Pfeifer MA; Schumer MP; Gelber DA
    Diabetes; 1997 Sep; 46 Suppl 2():S82-9. PubMed ID: 9285505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural-functional interactions in the therapeutic response of diabetic neuropathy.
    Sima AA; Greene DA
    Diabet Med; 1993; 10 Suppl 2():33S-34S. PubMed ID: 8334838
    [No Abstract]   [Full Text] [Related]  

  • 17. Medical therapy in the prevention of cataract.
    Brown NA; Bron AJ
    Trans Ophthalmol Soc U K (1962); 1985; 104 ( Pt 7)():748-54. PubMed ID: 3938085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of aldose reductase inhibitors on the progression of nerve damage.
    Greene DA; Sima AA
    Diabet Med; 1993; 10 Suppl 2():31S-32S. PubMed ID: 8334837
    [No Abstract]   [Full Text] [Related]  

  • 19. Aldose reductase inhibition in the treatment of diabetic neuropathy: where are we in 2004?
    Gabbay KH
    Curr Diab Rep; 2004 Dec; 4(6):405-8. PubMed ID: 15539002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent clinical experience with aldose reductase inhibitors.
    Krans HM
    Diabet Med; 1993; 10 Suppl 2():44S-48S. PubMed ID: 8334842
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.